Advertisement
REGN vs VRTX
Which Stock Would AI Choose? Regeneron Pharmaceuticals (REGN) vs. Vertex Pharmaceuticals (VRTX) Stock Comparison
Key Takeaways
- Both REGN and VRTX are large-cap biotechnology companies with strong commercial portfolios and robust pipelines, though they operate in distinct therapeutic areas.
- Recent quarterly results showed REGN delivering higher year-over-year revenue growth (approximately 17%) compared to VRTX (12%), supported by key products like Dupixent and Eylea HD.
- VRTX completed a significant $10 billion acquisition of Crinetics Pharmaceuticals in early September 2026, expanding into rare endocrine diseases, while REGN benefited from an analyst upgrade to Strong Buy.
- Stock prices have shown relative stability in recent market activity, with REGN trading near $785 and VRTX near $508 as of mid-September 2026, both below their 52-week highs.
- Analyst consensus for both remains Moderate Buy, with price targets implying modest upside potential amid broader sector sentiment.
- Relative performance highlights trade-offs in valuation metrics, with REGN generally exhibiting lower forward price-to-earnings ratios than VRTX.
Introduction
Regeneron Pharmaceuticals (REGN) and Vertex Pharmaceuticals (VRTX) represent two leading biotechnology firms frequently compared by investors seeking exposure to innovative drug development and commercial execution. This comparison examines their recent performance, business models, and market positioning to assist traders and portfolio managers evaluating relative value within the healthcare sector. Both stocks appeal to those focused on long-term growth in specialty pharmaceuticals, pipeline catalysts, and earnings stability amid evolving regulatory and competitive landscapes. The analysis draws on observable data from the past several weeks to highlight key contrasts without forward projections.
REGN Overview and Recent Performance
Regeneron Pharmaceuticals develops and commercializes therapies primarily in immunology, ophthalmology, and oncology. Its flagship product Dupixent, in collaboration with Sanofi, continues to drive substantial revenue growth. In the most recent reported quarter, the company posted revenue of approximately $4.3 billion, reflecting a 17% year-over-year increase, with earnings per share surpassing consensus estimates. Recent market activity has featured analyst support, including an upgrade to Strong Buy by at least one firm, contributing to a Moderate Buy consensus overall. Stock behavior in recent weeks has reflected broader biotech sentiment, with shares trading around $785 amid a 52-week range of roughly $541 to $859. Pipeline updates and collaboration revenues have supported sentiment, though the company faces typical sector risks such as competition and clinical timelines.
VRTX Overview and Recent Performance
Vertex Pharmaceuticals focuses on cystic fibrosis treatments alongside expanding areas such as gene editing and acute pain management. Its core cystic fibrosis franchise, including Trikafta, underpins consistent revenue, while newer products like Casgevy have seen label expansions. Second-quarter results showed revenue of $3.33 billion, up 12% year over year, prompting an upward revision to full-year guidance. The completion of the Crinetics Pharmaceuticals acquisition in early September 2026 added rare endocrine disease assets, broadening the portfolio. In recent market activity, shares have traded near $508 within a 52-week range of approximately $374 to $560. Analyst views remain supportive with a Moderate Buy consensus, and performance has been influenced by pipeline progress and acquisition integration considerations.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases a curated selection of high-performing AI trading bots from hundreds available on the platform. These bots trade thousands of different tickers across varied strategies, timeframes, and risk profiles, with only the most suitable for prevailing market conditions featured in the trending section. Available bots display a wide range of performance statistics, including win rates, profit factors, and drawdown metrics, allowing users to evaluate historical results objectively. The selection emphasizes diversity in trading styles to match different investor preferences. For those exploring automated trading opportunities involving stocks like REGN or VRTX, reviewing the latest trends on the platform provides additional context.
Head-to-Head Comparison
Regeneron Pharmaceuticals and Vertex Pharmaceuticals both operate in biotechnology but differ in core focus areas, with REGN emphasizing immunology and ophthalmology through key collaborations, while VRTX maintains leadership in cystic fibrosis and pursues diversification via acquisitions. Recent momentum shows REGN with stronger top-line growth in its latest quarter, contrasted by VRTX’s portfolio expansion through the Crinetics deal. Valuation metrics present trade-offs, as REGN generally trades at lower forward price-to-earnings multiples relative to VRTX. Risk factors include product concentration for both, alongside sector-wide exposure to regulatory approvals and competition. Market sentiment remains constructive for each based on analyst ratings, though relative positioning depends on individual tolerance for volatility and growth drivers in distinct therapeutic segments.
Tickeron AI Verdict
Based on observable factors such as trend consistency in recent earnings beats, pipeline stability, and relative positioning within the biotech sector, Tickeron’s AI models currently indicate a probabilistic preference toward VRTX due to its broader diversification efforts and steady revenue trajectory. However, REGN demonstrates competitive strength in growth metrics and valuation efficiency. Outcomes remain subject to ongoing market dynamics and company-specific developments, warranting continued monitoring rather than definitive allocation decisions.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is REGN is a Buy and VRTX is a StrongBuy.
REGN | VRTX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 65 | 82 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 2 Undervalued | 83 Overvalued | |
PROFIT vs RISK RATING 1..100 | 85 | 19 | |
SMR RATING 1..100 | 59 | 41 | |
PRICE GROWTH RATING 1..100 | 42 | 45 | |
P/E GROWTH RATING 1..100 | 14 | 31 | |
SEASONALITY SCORE 1..100 | 65 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
REGN's Valuation (2) in the Biotechnology industry is significantly better than the same rating for VRTX (83). This means that REGN’s stock grew significantly faster than VRTX’s over the last 12 months.
VRTX's Profit vs Risk Rating (19) in the Biotechnology industry is significantly better than the same rating for REGN (85). This means that VRTX’s stock grew significantly faster than REGN’s over the last 12 months.
VRTX's SMR Rating (41) in the Biotechnology industry is in the same range as REGN (59). This means that VRTX’s stock grew similarly to REGN’s over the last 12 months.
REGN's Price Growth Rating (42) in the Biotechnology industry is in the same range as VRTX (45). This means that REGN’s stock grew similarly to VRTX’s over the last 12 months.
REGN's P/E Growth Rating (14) in the Biotechnology industry is in the same range as VRTX (31). This means that REGN’s stock grew similarly to VRTX’s over the last 12 months.
| REGN | VRTX | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 43% | 2 days ago 59% |
| Stochastic ODDS (%) | 2 days ago 64% | 2 days ago 72% |
| Momentum ODDS (%) | 2 days ago 61% | 2 days ago 41% |
| MACD ODDS (%) | 2 days ago 57% | 2 days ago 49% |
| TrendWeek ODDS (%) | 2 days ago 65% | 2 days ago 67% |
| TrendMonth ODDS (%) | 2 days ago 61% | 2 days ago 34% |
| Advances ODDS (%) | 3 days ago 65% | 2 days ago 66% |
| Declines ODDS (%) | 14 days ago 55% | 9 days ago 41% |
| BollingerBands ODDS (%) | 4 days ago 54% | 2 days ago 58% |
| Aroon ODDS (%) | 2 days ago 66% | 2 days ago 68% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
REGN’s FA Score shows that 2 FA rating(s) are green while VRTX’s FA Score has 2 green FA rating(s).
- REGN’s FA Score: 2 green, 3 red.
- VRTX’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
REGN’s TA Score shows that 3 TA indicator(s) are bullish while VRTX’s TA Score has 5 bullish TA indicator(s).
- REGN’s TA Score: 3 bullish, 6 bearish.
- VRTX’s TA Score: 5 bullish, 4 bearish.
Price Growth
REGN (@Biotechnology) experienced а +3.51% price change this week, while VRTX (@Biotechnology) price change was +0.60% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.84%. For the same industry, the average monthly price growth was -10.68%, and the average quarterly price growth was +8.45%.
Reported Earning Dates
REGN is expected to report earnings on Oct 29, 2026.
VRTX is expected to report earnings on Nov 09, 2026.
Industries' Descriptions
@Biotechnology (-1.84% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
REGN and
Correlation & Price change
A.I.dvisor indicates that over the last year, REGN has been loosely correlated with PCVX. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if REGN jumps, then PCVX could also see price increases.
| Ticker / NAME | Correlation To REGN | 1D Price Change % | ||
|---|---|---|---|---|
| REGN | 100% | -0.26% | ||
| PCVX - REGN | 41% Loosely correlated | -4.28% | ||
| VRTX - REGN | 40% Loosely correlated | +0.26% | ||
| ARQT - REGN | 37% Loosely correlated | -5.04% | ||
| RPRX - REGN | 36% Loosely correlated | -1.49% | ||
| BMRN - REGN | 35% Loosely correlated | -1.83% | ||
More | ||||